RxDoctor Payments Data

Hassan Nasser, MD

Internal Medicine · Baltimore, MDNPI 1912961665

Payments from drug & device makers

$311in general payments, 2019–2025

Across 10 payments — averaging $31.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$144
  • Novo Nordisk$41
  • Lilly USA, LLC$39
  • Qiagen, LLC$20
  • Boehringer Ingelheim$19
  • Medline Industries LP$17
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$29294%
  • Education$196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$311 in reported general payments places this provider in the 55th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$181,911
Medicare patients
390
Services billed
2,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide185$189,381
EliquisApixaban153$158,572
JardianceEmpagliflozin132$146,375
TrulicityDulaglutide124$139,702
XareltoRivaroxaban55$65,513
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$62,035
EntrestoSacubitril/Valsartan38$54,752
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$45,304
RybelsusSemaglutide23$35,709
JanuviaSitagliptin Phosphate26$32,537
FarxigaDapagliflozin Propanediol20$23,107
MounjaroTirzepatide16$22,493
TradjentaLinagliptin18$18,499
JanumetSitagliptin Phos/Metformin Hcl21$17,375
LinzessLinaclotide18$16,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$41$225,090208 claims
Boehringer IngelheimJardiance, Tradjenta$19$164,874150 claims
Lilly USA, LLCTrulicity, Mounjaro$39$162,195140 claims
PfizerEliquis$16$158,572153 claims
GSKTrelegy Ellipta$14$62,03567 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →